Last reviewed · How we verify
Cyproheptadine Hydrochloride (CYPROHEPTADINE)
Cyproheptadine Hydrochloride (generic name: CYPROHEPTADINE) is a cyproheptadine Small molecule drug developed by Merck. It is currently FDA-approved (first approved 1961) for Allergic conjunctivitis, Allergic rhinitis, Dermatographic urticaria.
Cyproheptadine hydrochloride is a small molecule that acts as a histamine H1 receptor antagonist. It is used to treat conditions such as allergic rhinitis, hay fever, and seasonal allergic rhinitis (SAR).
At a glance
| Generic name | CYPROHEPTADINE |
|---|---|
| Sponsor | Merck |
| Drug class | cyproheptadine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 1961 |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Dermatographic urticaria
- Itching of skin
- Nasal congestion
- Nasal discharge
- Sneezing
- Urticaria
Common side effects
- Sedation and sleepiness
- Dizziness
- Disturbed coordination
- Confusion
- Restlessness
- Excitation
- Nervousness
- Tremor
- Irritability
- Insomnia
- Paresthesias
- Neuritis
Drug interactions
- fluoxetine
- paroxetine
- sertraline
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- The Use of Cyproheptadine in Pediatric Feeding Disorders (PHASE4)
- Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (PHASE4)
- Loratadine for the Prevention of G-CSF-related Bone Pain (PHASE2)
- The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis (NA)
- Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers (NA)
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyproheptadine Hydrochloride CI brief — competitive landscape report
- Cyproheptadine Hydrochloride updates RSS · CI watch RSS
Frequently asked questions about Cyproheptadine Hydrochloride
What is Cyproheptadine Hydrochloride?
What is Cyproheptadine Hydrochloride used for?
Who makes Cyproheptadine Hydrochloride?
What is the generic name of Cyproheptadine Hydrochloride?
What drug class is Cyproheptadine Hydrochloride in?
When was Cyproheptadine Hydrochloride approved?
What development phase is Cyproheptadine Hydrochloride in?
What are the side effects of Cyproheptadine Hydrochloride?
What does Cyproheptadine Hydrochloride target?
Related
- Drug class: All cyproheptadine drugs
- Target: All drugs targeting Histamine H1 receptor
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Dermatographic urticaria
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing